PharmaShots | Incisive News in 3 Shots

Subscribe Now

KITE

Kite (Gilead) and Arcellx Report the Expansion of its Collaboration Agreement for CART-DdBCMA in Multiple Myeloma

Kite (Gilead) and Arcellx Report the Expansion of its Collaboration Agreement for CART-DdBCMA in Multiple Myeloma

November 16, 2023

$Kite Reports P-II Study (ALYCANTE) Results of Yescarta (axicabtagene ciloleucel) for Relapsed/Refractory Large B-Cell Lymphoma$

Kite Reports P-II Study (ALYCANTE) Results of Yescarta (axicabtagene ciloleucel) for Relapsed/Refractory Large B-Cell Lymphoma

September 18, 2023

$Kite Reports Real-World Analysis Results of Tecartus (brexucabtagene autoleucel) for Relapsed/Refractory Mantle Cell Lymphoma$

Kite Reports Real-World Analysis Results of Tecartus (brexucabtagene autoleucel) for Relapsed/Refractory Mantle Cell Lymphoma

June 7, 2023

$Kite Reports P-III Study (ZUMA-7) Results of Yescarta for Initial Treatment of Relapsed/Refractory Large B-cell Lymphoma$

Kite Reports P-III Study (ZUMA-7) Results of Yescarta for Initial Treatment of Relapsed/Refractory Large B-cell Lymphoma

March 22, 2023

Kite Reports P-I/II Study (ZUMA-3) Results of Tecartus (brexucabtagene autoleucel) for B-Cell Acute Lymphoblastic Leukemia

Kite Reports P-I/II Study (ZUMA-3) Results of Tecartus (brexucabtagene autoleucel) for B-Cell Acute Lymphoblastic Leukemia

February 10, 2023

Kite’s Yescarta Receives EC’s Approval as 2L Treatment of Diffuse Large B-cell Lymphoma and High-grade B-cell Lymphoma

Kite’s Yescarta Receives EC’s Approval as 2L Treatment of Diffuse Large B-cell Lymphoma and High-grade B-cell Lymphoma

October 18, 2022

Contact Us

First Floor, B-66, Sector 63 Noida, Uttar Pradesh, INDIA - 201301
+91-120 428 0707
connect@pharmashots.com
Newsletter

Our Information

Follow Us